Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

5 Dirt-Cheap Stocks: Trick Or Treat?

Are the valuations 3i Group plc (LON:III), GKN plc (LON:GKN), J Sainsbury plc (LON:SBRY), Petrofac Limited (LON:PFC) and GlaxoSmithKline plc (LON:GSK) a trick or a treat?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

halloween

Value traps are something that all investors must be well aware of. Indeed, just because a company’s share price is cheap does not necessarily mean it’s a great investment. It could be cheap for a reason that harms its future performance, for example.

On the other hand, even with the FTSE 100 above 6,500 points, there could still be some bargains around. With that in mind, are these five shares worth buying at their current, low levels? In other words, are they tricks, or treats?

3i

With a price to earnings (P/E) ratio of just 7.9, 3i (LSE: III) is dirt cheap. That’s despite outperforming the FTSE 100 during the last year, with shares in 3i being up 6% versus a 3% fall for the FTSE 100.

Of course, 3i’s bottom line is volatile. That’s due to it being an investor in other companies, with start-up tech companies being a particular specialism of 3i. As a result, profitability can fluctuate considerably and, as was the case in 2012, turn to a loss.

Still, with a number of potential winners in its portfolio and a dividend yield of 3.4% that is covered 3.8 times by profit, now could be a great time to buy 3i – especially for long-term investors.

GKN

Automotive and aerospace specialist GKN (LSE: GKN) trades on a P/E ratio of just 11.8. Although this year is set to see profits fall by 6%, GKN has become a much more reliable stock in recent years since it became more involved in the steadier (compared to automotive) aerospace industry. As a result, profit has grown in each of the last four years.

With GKN set to return to growth next year with a bottom line rise of 6%, now could be a great time to buy a slice of the company. Furthermore, a payout ratio of just 31% suggests dividends can go much higher and GKN’s yield could expand considerably from the current 2.6%.

J Sainsbury

Clearly, J Sainsbury (LSE: SBRY) is going through a rough patch. The supermarket price war is taking its toll on the company’s bottom line and, although J Sainsbury remains highly profitable, shares in the company now trade at just 80% of their net asset value.

While dividends are being cut, J Sainsbury still yields over 5% and, more importantly, dividends remain well covered at two times earnings. With wage rises set to outstrip inflation next year for the first time in seven years, 2015 could be the year that J Sainsbury mounts a fight back.

Petrofac

With the oil price having fallen by over 25% this year, oil services company Petrofac (LSE: PFC) has seen its share price drop by 13% year-to-date. It now trades on a P/E ratio of just 10.1 and seems to offer great value for money.

For example, Petrofac is forecast to increase its bottom line by a superb 19% next year. This puts it on a price to earnings growth (PEG) ratio of just 0.5 and shows that upside potential does remain. Although the oil price could disappoint in the short run, Petrofac seems to be well-placed to deliver share price growth in 2015 and beyond.

GlaxoSmithKline

With a trailing P/E of just 12.6, GlaxoSmithKline (LSE: GSK) looks like a bargain – especially when the FTSE 100 has a P/E ratio of 13.8. However, the pharmaceutical major is due to report a decline in earnings of 17% in the current year, which means that its trailing P/E could soon rise to around 15.1.

Despite this, GlaxoSmithKline still looks like a great buy. It has a fantastic long term pipeline of new drugs and, with a yield of 5.7%, also has huge appeal as an income play. While the short term may be somewhat volatile due to potential restructuring and pressure from generic drugs, GlaxoSmithKline could prove to be a real treat in the long run.

Peter Stephens owns shares in GlaxoSmithKline, 3i, J Sainsbury and Petrofac. The Motley Fool has recommended shares in Glaxo and Petrofac.

More on Investing Articles

Investing Articles

The BP share price could face a brutal reckoning in 2026

Harvey Jones is worried about the outlook for the BP share price, as the global economy struggles and experts warn…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

How on earth did Lloyds shares explode 75% in 2025?

Harvey Jones has been pleasantly surprised by the blistering performance of Lloyds shares over the last year or two. Will…

Read more »

Group of four young adults toasting with Flying Horse cans in Brazil
Investing Articles

Down 56% with a 4.8% yield and P/E of 13 – are Diageo shares a generational bargain?

When Harvey Jones bought Diageo shares he never dreamed they'd perform this badly. Now he's wondering if they're just too…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

Could these 3 holdings in my Stocks and Shares ISA really increase in value by 25% in 2026?

James Beard’s been looking at the 12-month share price forecasts for some of the positions in his Stocks and Shares…

Read more »

National Grid engineers at a substation
Investing Articles

2 reasons I‘m not touching National Grid shares with a bargepole!

Many private investors like the passive income prospects they see in National Grid shares. So why does our writer not…

Read more »

Number 5 foil balloon and gold confetti on black.
Investing Articles

£10,000 invested in Greggs shares 5 years ago would have generated this much in dividends…

Those who invested in Greggs shares five years ago have seen little share price growth. However, the dividends have been…

Read more »

Rolls-Royce Hydrogen Test Rig at Loughborough University
Growth Shares

Here is the Rolls-Royce share price performance for 2023, 2024, and 2025

Where will the Rolls-Royce share price be at the end of 2026? Looking at previous years might help us find…

Read more »

Investing Articles

This FTSE 250 stock could rocket 49%, say brokers

Ben McPoland takes a closer look at a market-leading FTSE 250 company that generates plenty of cash and has begun…

Read more »